Patients with ER+/HER2+ breast cancer had a worse prognosis compared to those with ER+/HER2- disease in the pre-trastuzumab treatment era, who were more frequently treated with chemotherapy and escalation endocrine therapy. Here, ESR1 is linked to breast carcinoma.